Fiona Marshall (pharmacologist)

Last updated

Fiona Marshall
Fiona Marshall at NIH's 2017 Daly lecture.jpg
Marshall speaking at the National Institutes of Health 2017 Daly lecture
Born
Fiona Hamilton Marshall
Alma mater University of Bath (BSc)
University of Cambridge (PhD)
Scientific career
Fields Drug discovery
GPCRs
Neuroscience [1] [2]
Institutions Novartis
Merck & Co.
GlaxoSmithKline
Thesis Cholecystokinin/dopamine interactions in the rat basal ganglia  (1990)
Doctoral advisor John Hughes

Fiona Hamilton Marshall FRS FMedSci is a British pharmacologist, biotech-founder and President of Biomedical Research at Novartis. [3] [2] [4] She founded and previously served as Chief Scientific Officer at Heptares Therapeutic, [2] which was acquired by the Japanese biopharmaceutical company Sosei, where she served as Vice President. [1] She was elected Fellow of the Academy of Medical Sciences in 2016 [5] and the Royal Society in 2021. [6]

Contents

Early life and education

Marshall became interested in biology, chemistry and physics at high school. [7] As a teenager she won a prize at a national physics competition. Marshall graduated with a First class degree in biochemistry from the University of Bath in 1987. [8] She moved to the University of Cambridge for her graduate studies, [9] where she focussed on neuroscience under the supervision of John Hughes. [9] Her doctoral advisor served as director of the University of Cambridge Parke-Davis Research Centre, which inspired Marshall to work in the pharmaceutical industry. [8]

Research and career

After earning her doctorate Marshall moved to GlaxoSmithKline where she joined the department of neuropharmacology. Marshall worked alongside Patrick Humphrey and Mike Tyers at GlaxoSmithKline. Here she investigated the receptors that are activated by neurotransmitters and microbial metabolites. [10] After only nine years, Marshall was made Head of Molecular Pharmacology in 1999. [8] She eventually moved from the neuropharmacology team to a group working on G protein-coupled receptors. [8] Almost a third of drugs work through these G protein-coupled receptors. [7] She was the first to identify and describe the cloning and structural requirements of the GABAB receptor, a member of the GPCR family. She was headhunted by Millennium Pharmaceuticals and joined as their Director of Molecular Pharmacology in 2000. [8] When her children were young, Marshall took time away from her work in the pharmaceutical Industry to work more flexibly as a consultant.. [7]

Working with Malcolm Weir, and together with Christopher Tate and Richard Henderson, Marshall founded Heptares Therapeutics, [11] a spin-out from the Medical Research Council (MRC). [12] Heptares makes use of technologies developed by the Medical Research Council that allow the crystallisation and characterisation of G protein-coupled receptors for drug design.  This included the first crystal structure of the GLP-1 receptor. [13] One of the cancer therapy drug candidates developed by Heptares was licensed to AstraZeneca in 2015. Later that year, Heptares was incorporated into the Japanese bio-pharmaceutical company Sosei. [7] [2]

Marshall joined Merck & Co as Head of the UK Discovery Research Centre in 2018. In this capacity she concentrated on She serves on the council of the Academy of Medical Sciences and the Medical Research Council. diseases of ageing. In 2019 she was made Global Head of Neuroscience   Discovery, where she spent two years before being appointed Senior Vice President of Discovery, Preclinical & Translational Medicine Research. [14] In 2022 she became the President of Biomedical Research at Novartis. [15]

Awards and honours

Selected publications

Related Research Articles

<span class="mw-page-title-main">Pharmacology</span> Branch of biology concerning drugs

Pharmacology is the science of drugs and medications, including a substance's origin, composition, pharmacokinetics, pharmacodynamics, therapeutic use, and toxicology. More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. If substances have medicinal properties, they are considered pharmaceuticals.

<span class="mw-page-title-main">GABA receptor</span> Receptors that respond to gamma-aminobutyric acid

The GABA receptors are a class of receptors that respond to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory compound in the mature vertebrate central nervous system. There are two classes of GABA receptors: GABAA and GABAB. GABAA receptors are ligand-gated ion channels ; whereas GABAB receptors are G protein-coupled receptors, also called metabotropic receptors.

GABAB receptors (GABABR) are G-protein coupled receptors for gamma-aminobutyric acid (GABA), therefore making them metabotropic receptors, that are linked via G-proteins to potassium channels. The changing potassium concentrations hyperpolarize the cell at the end of an action potential. The reversal potential of the GABAB-mediated IPSP is −100 mV, which is much more hyperpolarized than the GABAA IPSP. GABAB receptors are found in the central nervous system and the autonomic division of the peripheral nervous system.

The GABAA-rho receptor is a subclass of GABAA receptors composed entirely of rho (ρ) subunits. GABAA receptors including those of the ρ-subclass are ligand-gated ion channels responsible for mediating the effects of gamma-amino butyric acid (GABA), the major inhibitory neurotransmitter in the brain. The GABAA-ρ receptor, like other GABAA receptors, is expressed in many areas of the brain, but in contrast to other GABAA receptors, the GABAA-ρ receptor has especially high expression in the retina.

<span class="mw-page-title-main">Richard Henderson (biologist)</span> British biologist

Richard Henderson is a British molecular biologist and biophysicist and pioneer in the field of electron microscopy of biological molecules. Henderson shared the Nobel Prize in Chemistry in 2017 with Jacques Dubochet and Joachim Frank. "Thanks to his work, we can look at individual atoms of living nature, thanks to cryo-electron microscopes we can see details without destroying samples, and for this he won the Nobel Prize in Chemistry."

<span class="mw-page-title-main">Fiona Watt</span> British scientist

Fiona Watt, is a British scientist who is internationally known for her contributions to the field of stem cell biology. In the 1980s, when the field was in its infancy, she highlighted key characteristics of stem cells and their environment that laid the foundation for much present day research. She is currently Director of the European Molecular Biology Organization (EMBO). after previously serving as director of the Centre for Stem Cells & Regenerative Medicine at King's College London, and Executive Chair of the Medical Research Council (MRC), the first woman to lead the MRC since its foundation in 1913.

<span class="mw-page-title-main">CGP-7930</span> Chemical compound

CGP-7930 was the first positive allosteric modulator of GABAB receptors described in literature. CGP7930 is also a GABAA receptor positive allosteric modulator and a blocker of Potassium channels.

<span class="mw-page-title-main">Stuart Cull-Candy</span> British neuroscientist

Stuart Graham Cull-Candy is a British neuroscientist. He holds the Gaddum Chair of Pharmacology and a personal Chair in Neuroscience at University College London. He is also a member of the Faculty of 1000 and held a Royal Society - Wolfson Research position.

Ann Jacqueline Hunter CBE FMedSci FBPharmacolS FRSB is a British scientist who is a board director of BenevolentAI. Hunter is also a visiting professor at St George's Hospital Medical School and Imperial College. She is Chair of the Trustees of the Sainsbury Laboratories at Norwich, chair of the board of the Stevenage Bioscience Catalyst and chair of the board of Brainomix. She was previously CEO of the Biotechnology and Biological Sciences Research Council.

<span class="mw-page-title-main">Annette Dolphin</span> Professor of Pharmacology

Annette Catherine Dolphin is a Professor of Pharmacology in the Department of Neuroscience, Physiology and Pharmacology at University College London (UCL).

<span class="mw-page-title-main">Ben G. Davis</span> Professor of Chemistry, in the Department of Chemistry at the University of Oxford

Benjamin Guy Davis is Professor of Chemical biology in the Department of Pharmacology and a member of the Faculty in the Department of Chemistry at the University of Oxford and a Fellow of Pembroke College, Oxford. He holds the role of Science Director for Next Generation Chemistry (2019-2024) and Deputy Director (2020-) at the Rosalind Franklin Institute.

<span class="mw-page-title-main">Antony Galione</span> British pharmacologist (born 1963)

Antony Giuseppe Galione is a British pharmacologist. He is a professor and Wellcome Trust senior investigator in the Department of Pharmacology at the University of Oxford.

<span class="mw-page-title-main">David Lodge (scientist)</span> British neuroscientist

David Lodge is a research fellow in the Department of Physiology and Pharmacology at the University of Bristol.

Professor Norman Bowery, was a British pharmacologist and former Head of Division of Neuroscience and Chair of Pharmacology at the University of Birmingham from 1995 to 2004. He was president of the British Pharmacological Society from 1995 to 1997 and from 1999 to 2000.

<span class="mw-page-title-main">E. Yvonne Jones</span> Director of the Cancer Research UK Receptor Structure Research Group

(Edith) Yvonne JonesFLSW is director of the Cancer Research UK Receptor Structure Research Group at the University of Oxford and a Fellow of Jesus College, Oxford. She is widely known for her research on the molecular biology of cell surface receptors and signalling complexes.

<span class="mw-page-title-main">3-APPA</span> Chemical compound

3-Aminopropylphosphinic acid, also known in the literature as 3-APPA or CGP 27492, is a compound used in scientific research which acts as an agonist at the GABAB receptor. It is part of a class of phosphinic acid GABAB agonists, which also includes SKF-97,541. It has a binding affinity (pKi) to the GABAB receptor of 8.30.

Frances Mary Platt is a British biochemist and pharmacologist who is a professor at the University of Oxford. Her research investigates rare genetic disorders known as lysosomal storage diseases, progressive conditions that lead to neurodegeneration. She was elected Fellow of the Royal Society in 2021.

Clare Bryant FLSW is a British veterinary scientist and clinical pharmacologist who is a professor at the University of Cambridge. She specialises in innate immunity. Bryant is a Fellow of Queens' College, Cambridge and of the British Pharmacological Society.

Susan Mary Lea is a British biologist who serves as chief of the center for structural biology at the National Cancer Institute. Her research investigates host-pathogen interactions and biomolecular pathways. She was elected a Fellow of the Royal Society in 2022.

Arthur Henry Weston is emeritus professor at the University of Manchester, where he was previously Leech Professor of Pharmacology from 1989-2011.

References

  1. 1 2 Fiona Marshall publications indexed by Google Scholar OOjs UI icon edit-ltr-progressive.svg
  2. 1 2 3 4 Fiona Marshall publications from Europe PubMed Central
  3. Fishburn, C. Simone. "Reshaping research at Novartis". BioCentury. Retrieved 12 June 2024.
  4. Carroll, John. "NIBR chief Jay Bradner joins the exodus at Novartis, handing the keys to Fiona Marshall". Endpoints News. Retrieved 1 September 2022.
  5. "Dr Fiona Marshall | The Academy of Medical Sciences". acmedsci.ac.uk.
  6. 1 2 Anon (2021). "Fiona Marshall". royalsociety.org. Royal Society. Retrieved 14 May 2021.
  7. 1 2 3 4 5 "Meet the infocus ambassadors - Fiona Marshall - Innovate UK". innovateuk.blog.gov.uk. Retrieved 14 May 2021.
  8. 1 2 3 4 5 6 "Dr Fiona Marshall FMedSci, FBPhS, FRSB: oration". bath.ac.uk. Retrieved 14 May 2021.
  9. 1 2 Marshall, Fiona Hamilton (1990). Cholecystokinin/dopamine interactions in the rat basal ganglia. cam.ac.uk (PhD thesis). University of Cambridge. OCLC   82547258. EThOS   uk.bl.ethos.386170.
  10. 1 2 Therapeutics, Heptares. "Heptares Chief Scientific Officer and Co-founder - Dr Fiona Marshall - Elected as a Fellow of the Academy of Medical Sciences". prnewswire.com (Press release). Retrieved 14 May 2021.
  11. Mike, Scialom (19 October 2018). "It's a new day for Sosei Heptares". Cambridge Independent. Retrieved 28 September 2023.
  12. 1 2 "Dr Fiona Marshall". bps.ac.uk.
  13. "Crystal structure of the GLP-1 receptor bound to a peptide agonist | Nature". Nature .
  14. "Fiona Marshall elected a fellow of the Royal Society". msd.com. Retrieved 14 May 2021.
  15. "Novartis Nabs Merck Veteran to Helm BioMedical Institutes". BioSpace. Retrieved 12 June 2024.
  16. "Malcolm Campbell Memorial Prize winners 2015 – RSC Medicinal Chemistry Blog". rsc.org. Retrieved 14 May 2021.
  17. "BPS Vane Medal". bps.ac.uk. British Pharmacological Society.